Morgan Stanley lowered the firm’s price target on Align Technology (ALGN) to $249 from $272 and keeps an Overweight rating on the shares. While policy will be “front and center” with varying degrees of exposure, or lack there of, across the Healthcare Services and Technology space, the focus will also be on indications of underlying utilization trends across MCOs, distributors, providers, labs, animal and dental into Q1, the analyst tells investors in a preview for the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGN:
- GOOGL, ON, ALGN: Morningstar (MORN) Names Top-Rated Stocks That Are Undervalued
- Align Technology announces commercial availability of Invisalign with mandibula
- Align Technology price target lowered to $250 from $295 at Mizuho
- Positive Outlook for Align Technology Amidst Stabilizing Market Share and Competitive Pressures
- Stifel says Angelalign case volume supports Invisalign stabilization thesis